donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
INDP Indaptus Therapeutics
2.550
-0.040-1.54%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Total revenue
0 0 0 0
Operating revenue
-- 0 -- 0 -- 0 -- 0
Cost of revenue
Gross profit
Operating expense
-7.74% 3.87M 454.11% 3.4M 114.74% 7.73M 318.77% 3.22M
Selling and administrative expenses
-1% 2.36M 1594.09% 2.1M 451.33% 5.21M 446.05% 2.27M
-General and administrative expense
-1% 2.36M 1594.09% 2.1M 451.33% 5.21M 446.05% 2.27M
Research and development costs
-16.65% 1.51M 164.86% 1.3M -4.97% 2.52M 168.26% 944.64K
Operating profit
7.74% -3.87M -454.11% -3.4M -114.74% -7.73M -318.77% -3.22M
Net non-operating interest income expense
17.26% 17.72K
Non-operating interest income
-- -- -- -- 17.26% 17.72K -- --
Other net income (expense)
101.06% 33.76K 2275.74% 36.92K
Other non- operating income (expenses)
-- 33.76K 2275.74% 36.92K -- -- -- --
Income before tax
48.3% -3.84M -449.48% -3.37M -115.15% -7.71M -317.59% -3.22M
Income tax
Net income
48.39% -3.84M -449.48% -3.37M -115.15% -7.71M -317.59% -3.22M
Net income continuous Operations
48.39% -3.84M -449.48% -3.37M -115.15% -7.71M -317.59% -3.22M
Minority interest income
Net income attributable to the parent company
48.39% -3.84M -449.48% -3.37M -115.15% -7.71M -317.59% -3.22M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
48.39% -3.84M -449.48% -3.37M -115.15% -7.71M -317.59% -3.22M
Basic earnings per share
66.54% -0.46 -261.92% -0.41 -185.07% -1.89 -173.34% -0.3895
Diluted earnings per share
66.54% -0.46 -261.92% -0.41 -185.07% -1.89 -173.34% -0.3895
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
----Unqualified Opinion--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
CEO: Meckler, Jeffrey A.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...